EGFR and neoplasm: Meanwhile, molecular screening of sacroiliac bone-biopsy-tumor-tissue by a large gene new-generation sequencing (NGS) panel analysis identified EGFR 19 exon p.L747-P753 delinsS (33.9%), EGFR 19 exon p.L747S mutation (0.90%), TP53 exon8 p.V272L mutation (34.17%), MET (CN=9), CCNE1 (CN=11), RICTOR (CN=9), ATK3 (CN=9), CDK6 (CN=9), HGF (CN=9) amplification, microsatellite stable, and a level of 1.67Mut/Mb in tumor mutation burden.